Skip to content

Study in patients having a weakened immune system using antibiotic

A Prospective, Open label, Single arm, Multi-centric, Investigator initiated study (IIS) for evaluation of efficacy and safety of Levonadifloxacin (IV And Oral) for Gram-Positive Bacterial Infection in Immunocompromised patients.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/029431
Enrollment
112
Registered
2020-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified

Interventions

Intervention1: EMROK &/or EMROK â?? O (Levonadifloxacin): Levonadifloxacin IV 800 mg (each vial contains Levonadifloxacin 100 ml containing 8mg/ml) And Levonadifloxacin tablets (each tablet contains L

Sponsors

Dr P Saravanan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The Patients must meet ALL the following criteria: 1. Male or female subjects with 18 years and above of age 2. Subjects must be willing to participate in the study and provide a written informed consent 3. Patient diagnosed with gram positive bacterial infection in Immunocompromised condition including but not limited to Immunodeficiency and immunosuppressive drug therapy by International Classification of Disease (ICD-10 version 2019) to be treated with Levonadifloxacin (IV or Oral) as per investigatorâ??s discretion.

Exclusion criteria

Exclusion criteria: The Patients must not meet any the following criteria: 1. Subjects with history of hypersensitivity to any of the study drugs or same class of drugs 2. Subjects who received any experimental drug within 30 days prior to enrolment 3. Subjects who, in the judgment of the Investigator, are likely to be noncompliant or uncooperative during the study 4. Subjects with any abnormality that the Investigator deems to be clinically relevant, either on medical history, physical examination or ECG

Design outcomes

Primary

MeasureTime frame
EfficacyTimepoint: Primary end point : Clinical Response on Day 4, End of Treatment (EOT) and Test of Cure (TOC) Secondary end point : Microbiological Response on End of Treatment (EOT)

Secondary

MeasureTime frame
Safety - Tolerability EndpointTimepoint: Safety evaluation will be based on Adverse Events (AEs) reported, vital signs and physical examination findings, clinical laboratory evaluation, and ECG collected during the study.

Countries

India

Contacts

Public ContactDr Khokan Debnath

Wockhardt Limited

PSonone@wockhardt.com02226596447

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026